KZA — Kazia Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- AU$18.24m
- AU$14.80m
- AU$0.02m
Brief: Kazia Therapeutics Says Loss For Year Attributable A$24.6 Million
Brief: Kazia Therapeutics Reports Promising Interim Data From Combination Study Of Paxalisib With Radiotherapy In Treatment Of Brain Metastases
Kazia up on promising interim data from brain tumor study
U.S. STOCKS ON THE MOVE-Freshworks, Loews
U.S. STOCKS ON THE MOVE-Boeing Co, Celyad, EVO Payments
U.S. STOCKS ON THE MOVE-Kraft Heinz, Netflix Inc, Rocket Companies, Resolute Forest Products
Australia's Kazia climbs on rare-disease tag for pediatric cancer drug
Brief: Us FDA Awards Rare Pediatric Disease Designation To Paxalisib
Brief: U.S. FDA Awards Orphan Drug Designation To Paxalisib For AT/RT, A Rare Form Of Childhood Brain Cancer
Australia's Kazia climbs on U.S. FDA's orphan drug status for cancer drug
Brief: Kazia Therapeutics Says U.S. FDA Awards Orphan Drug Designation To Paxalisib
Brief: Kazia Says Phase II Study Of Paxalisib In Brain Metastases Advances To Expansion Stage In Breast Cancer Brain Metastases Cohort
Brief: Kazia Presents Positive Final Data From Phase II Study Of Paxalisib In Newly Diagnosed Glioblastoma At Asco Conference
Brief: Kazia Therapeutics Establishes 'At-The-Market' Equity Program With Oppenheimer & Co
Australia Stock Exchange release from KAZIA THERAPEUTI : Kazia to present at two conferences
Australia Stock Exchange release from KAZIA THERAPEUTI : Change in substantial holding
Australia Stock Exchange release from KAZIA THERAPEUTI : First patient into Cornell keto study
Australia Stock Exchange release from KAZIA THERAPEUTI : PRE_NR Ends: 09:55:11
Brief: Kazia Therapeutics Posts Loss For Half-Year Attributable Of A$13.0 Million